Department of Preventive and Social Medicine, JIPMER PSM, Chennai, India.
Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education, Puducherry, India
BMJ Open. 2022 Mar 24;12(3):e055226. doi: 10.1136/bmjopen-2021-055226.
To explore the various stakeholders' perspectives on barriers and facilitators for medication adherence among patients with cardiovascular diseases (CVDs) and diabetes mellitus (DM)in India.
Systematic review of qualitative studies.
A comprehensive systematic search was conducted in Medline, Cochrane Library, Science Direct and Google Scholar from January 2010 to July 2020. We included all qualitative peer-reviewed studies, reporting barriers and facilitators of medication adherence, from India, for our current review.
Data extraction was performed by two independent authors who also assessed the quality of included studies using the Critical Appraisal Skills Programme criteria. This qualitative evidence synthesis adhered to the enhancing transparency in reporting the synthesis of qualitative research checklist RESULTS: In total, 18 studies were included. Major barriers reported were lack of understanding about the disease, complications related to non-adherence, followed by forgetfulness, lack of family support and risk communication. Health system-related barriers such as accessibility, affordability and acceptability were also reported by majority of the studies. Creation of peer support groups, digital reminder systems, integration of native Indian systems of India, physiotherapy and geriatric clinics at the primary healthcare level and innovations in patient care were suggested to counter these barriers in medication adherence.
Such patient-specific targeted interventions need to be developed to achieve better control among patients with CVD and DM.PROSPERO registration numberCRD42020199529.
探讨印度心血管疾病(CVD)和糖尿病(DM)患者药物依从性的障碍和促进因素的各种利益相关者的观点。
定性研究的系统评价。
从 2010 年 1 月至 2020 年 7 月,我们在 Medline、Cochrane 图书馆、Science Direct 和 Google Scholar 进行了全面的系统搜索。我们纳入了所有来自印度的定性同行评议研究,这些研究报告了药物依从性的障碍和促进因素,用于我们目前的综述。
由两位独立作者进行数据提取,他们还使用关键评估技能计划标准评估了纳入研究的质量。本定性证据综合遵循提高报告定性研究综合透明度检查表的要求。
共纳入 18 项研究。报告的主要障碍包括对疾病缺乏了解、与不依从相关的并发症,其次是健忘、缺乏家庭支持和风险沟通。大多数研究还报告了与卫生系统相关的障碍,如可及性、可负担性和可接受性。为了克服药物依从性方面的这些障碍,建议创建同伴支持小组、数字提醒系统、整合印度本土系统、物理治疗和初级保健水平的老年病诊所以及创新的患者护理。
需要制定针对患者的特定干预措施,以实现 CVD 和 DM 患者更好的控制。PROSPERO 注册号 CRD42020199529。